Kolkata: Patient Service Programs (PSPs) are rapidly emerging as a cornerstone of modern healthcare, shifting the approach from one-time prescriptions to continuous patient engagement and improved health outcomes. While globally PSPs represent a USD 70 billion industry, in India the segment is still at a nascent stage.
Traditionally, PSPs in India were largely driven by multinational pharmaceutical companies, with Saarathi Healthcare leading the way in chronic disease management programs. With QMS Medical Allied Services Ltd. (QMS MAS) acquiring a majority stake in Saarathi — and moving towards full ownership — Indian pharma companies now have greater access to patient engagement models that are reshaping the country’s healthcare delivery.
“Our vision is to redefine PSPs as tech-enabled ecosystems that not only support patients but also drive measurable health outcomes,” said Mahesh Makhija, Founder, Chairman & Managing Director, QMS MAS.
Scale & Reach
- QMS MAS and Saarathi have supported 2.5 lakh patients across 100+ cities, covering diabetes, cardiology, respiratory care, and other chronic conditions.
- The company works with 130 institutional clients, including 50 leading pharma companies, across 5,000+ pin codes.
- Its healthcare network includes 900+ dieticians and 135 certified DMLTs, supported by advanced diagnostic devices with a 35 km service radius.
Beyond PSPs: Building a Holistic Healthcare Platform
With 31 years of experience, QMS MAS has grown into a trusted partner for pharmaceutical companies, connecting pharma, doctors, and patients.
Highlights of its diversified portfolio include:
- Launch of its own Q-Devices brand with cricket legend Kapil Dev as brand ambassador.
- Expansion into hospital supply solutions — stents, surgical instruments, and consumables.
- Integration with Saarathi’s expertise in patient engagement to deepen PSP models.
The full acquisition of Saarathi will enable QMS MAS to:
- Seamlessly integrate Saarathi’s PSP frameworks.
- Scale programs nationwide with greater efficiency.
- Innovate delivery models through digital health, AI-based screening, real-time monitoring, and advanced analytics.
Driving Growth with Purpose
In Q1 FY26, QMS MAS posted 54% revenue growth and 31.65% PAT growth, backed by regulatory clarity, operational efficiency, and expansion initiatives. At the core of this growth is the company’s patient-first philosophy, balancing profitability with social impact.
Looking Ahead
India’s chronic care demands extend beyond prescriptions — requiring education, counselling, lifestyle management, and therapy adherence. QMS MAS is bridging these critical gaps by evolving PSPs into wellness-driven ecosystems.
Over the next five years, PSPs in India are set to transform into technology-driven engagement platforms, integrating pharma, healthcare professionals, insurers, corporates, and patients. With its scale, Saarathi’s legacy, and innovation-focused approach, QMS MAS aims to lead this evolution — building trust, improving outcomes, and empowering patients across India.
